BioCentury
ARTICLE | Emerging Company Profile

Proxygen’s knockout take on targeted protein degradation

Emerging Company Profile: Vienna’s Proxygen is taking a ligase-agnostic approach to finding molecular glues with therapeutic effects

March 6, 2021 2:34 AM UTC

Austrian newco Proxygen is identifying cancer therapies that act via protein degradation by screening candidates in cells that can’t send proteins to the trash.

Founded last May, Proxygen GmbH has raised seed funding from the Austrian government and undisclosed private investors, and is in the process of raising a series A round. ...

BCIQ Company Profiles

Proxygen GmbH